Oncopharmpod
Acalabrutinb + BR and sotorasib + panitumumab
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:08:47
- Mas informaciones
Informações:
Sinopsis
FDA approves two new treatment regimens: 1. Acalabrutinib + BR for untreated mantle cell lymphoma patients deemed ineligible for autologous HSCT 2. Sotorasib + panitumumab for KRAS-G12C mutated metastatic colorectal cancer (after chemotherapy, including oxaliplatin and irinotecan)
